WORCESTER, Mass., June 5, 2008 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, has commenced dosing of patients in a Phase III clinical trial of the Company's flagship product, Generex Oral-lyn(tm), an oral insulin spray.
